The Phase IIa human clinical trial to be conducted in the US is designed to investigate the safety and clinical outcomes of topically applied GLYC-101 compared to placebo in subjects undergoing carbon dioxide laser skin resurfacing.
GLYC-101 has already completed a Phase II human clinical trial in Australia for the treatment of chronic venous skin ulcers. Glycotex intends to develop GLYC-101 for a wide range of human wound healing and tissue repair applications including burn wounds, post surgical wounds, diabetic ulcers and chronic venous ulcers.